Compare ASTRAZENECA PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ABBOTT INDIA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ABBOTT INDIA ASTRAZENECA PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 93.6 55.5 168.5% View Chart
P/BV x 28.4 16.5 172.4% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ASTRAZENECA PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ABBOTT INDIA
Mar-19
ASTRAZENECA PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,2788,834 14.5%   
Low Rs8835,458 16.2%   
Sales per share (Unadj.) Rs228.41,731.1 13.2%  
Earnings per share (Unadj.) Rs10.4211.9 4.9%  
Cash flow per share (Unadj.) Rs16.3219.9 7.4%  
Dividends per share (Unadj.) Rs065.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs98.8945.2 10.4%  
Shares outstanding (eoy) m25.0021.25 117.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.1 114.6%   
Avg P/E ratio x104.233.7 309.1%  
P/CF ratio (eoy) x66.432.5 204.4%  
Price / Book Value ratio x10.97.6 144.7%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m27,008151,848 17.8%   
No. of employees `0001.43.5 38.9%   
Total wages/salary Rs m1,5354,356 35.2%   
Avg. sales/employee Rs Th4,210.910,555.5 39.9%   
Avg. wages/employee Rs Th1,132.21,249.9 90.6%   
Avg. net profit/employee Rs Th191.11,292.2 14.8%   
INCOME DATA
Net Sales Rs m5,71036,786 15.5%  
Other income Rs m1231,133 10.8%   
Total revenues Rs m5,83337,919 15.4%   
Gross profit Rs m4636,047 7.7%  
Depreciation Rs m147169 87.1%   
Interest Rs m023 0.0%   
Profit before tax Rs m4386,989 6.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,485 7.2%   
Profit after tax Rs m2594,503 5.8%  
Gross profit margin %8.116.4 49.3%  
Effective tax rate %40.835.6 114.9%   
Net profit margin %4.512.2 37.1%  
BALANCE SHEET DATA
Current assets Rs m3,20927,610 11.6%   
Current liabilities Rs m2,0708,569 24.2%   
Net working cap to sales %20.051.8 38.6%  
Current ratio x1.63.2 48.1%  
Inventory Days Days7260 120.1%  
Debtors Days Days3527 127.5%  
Net fixed assets Rs m7901,057 74.8%   
Share capital Rs m50213 23.5%   
"Free" reserves Rs m2,41919,873 12.2%   
Net worth Rs m2,46920,086 12.3%   
Long term debt Rs m00-   
Total assets Rs m4,60529,409 15.7%  
Interest coverage xNM311.6-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.3 99.1%   
Return on assets %5.615.4 36.6%  
Return on equity %10.522.4 46.8%  
Return on capital %17.734.9 50.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m300369 81.2%   
Fx outflow Rs m2,0154,918 41.0%   
Net fx Rs m-1,715-4,549 37.7%   
CASH FLOW
From Operations Rs m884,991 1.8%  
From Investments Rs m-94-2,570 3.6%  
From Financial Activity Rs mNA-1,428 0.0%  
Net Cashflow Rs m-6993 -0.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 15.7 0.1 15,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   12,856 18,270 70.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  NOVARTIS  FRESENIUS KABI ONCO.  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Slow Economy? There's Still Good Money to Be Made in the Markets(Podcast)

Indian stock markets mostly remained in the negative zone during the week except for Wednesday.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 20, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS